Nonendometrioid endometrial carcinomas

Seminars in Diagnostic Pathology

Volumn 27, Issue 4, 2010, Pages 241-260

  Lim, Diana ^a   Oliva, Esther ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Carcinoma; Clear cell; Endometrium; Neuroendocrine; Serous; Squamous cell; Transitional cell; Undifferentiated

Indexed keywords

CA 125 ANTIGEN; CYTOKERATIN 7; EPITHELIAL MEMBRANE ANTIGEN; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53; TRASTUZUMAB; VIMENTIN;

ARTICLE; BREAST METASTASIS; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DRUG RESPONSE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METAPLASIA; NONHUMAN; OVARY METASTASIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA;

CARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 78650184758     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2010.09.004     Document Type: Article

References (229)

1. Clement P.B., Young R.H. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 2004, 11:117-142.
2. Matthews R.P., Hutchinson-Colas J., Maiman M., et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997, 65:206-212.
3. Bland A.E., Calingaert B., Secord A.A., et al. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol 2009, 112:150-154.
4. Silva E.G., Tornos C., Malpica A., et al. Uterine neoplasms in patients treated with tamoxifen. J Cell Biochem 1995, (Suppl 23):179-183.
5. Chan J.K., Manuel M.R., Cheung M.K., et al. Breast cancer followed by corpus cancer: Is there a higher risk for aggressive histologic subtypes?. Gynecol Oncol 2006, 102:508-512.
6. Gallion H.H., van Nagell J.R., Donaldson E.S., et al. Endometrial cancer following radiation therapy for cervical cancer. Gynecol Oncol 1987, 27:76-83.
7. Parkash V., Carcangiu M.L. Uterine papillary serous carcinoma after radiation therapy for carcinoma of the cervix. Cancer 1992, 69:496-501.
8. Carcangiu M.L., Radice P., Casalini P., et al. Lynch syndrome-Related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types. Int J Surg Pathol 2010, 18:21-26.
9. Lavie O., Ben-Arie A., Gemer O. Possible association between BRCA-1 carriers and incidence of uterine papillary serous carcinoma (UPSC). Int J Gynecol Cancer 2008, 18:1150.
10. Lavie O., Ben-Arie A., Pilip A., et al. BRCA2 germ line mutation in a woman with uterine serous papillary carcinoma-Case report. Gynecol Oncol 2005, 99:486-488.
11. Ng J.S., Han A.C., Edelson M.I., et al. Uterine papillary serous carcinoma presenting as distant lymph node metastasis. Gynecol Oncol 2001, 80:417-420.
12. Gu M., Shi W., Barakat R.R., et al. Pap smears in women with endometrial carcinoma. Acta Cytol 2001, 45:555-560.
13. Park J.Y., Kim H.S., Hong S.R., et al. Cytologic findings of cervicovaginal smears in women with uterine papillary serous carcinoma. J Korean Med Sci 2005, 20:93-97.
14. Tseng P.C., Sprance H.E., Carcangiu M.L., et al. CA 125, NB/70K, and lipid-associated sialic acid in monitoring uterine papillary serous carcinoma. Obstet Gynecol 1989, 74(3 Pt 1):384-387.
15. Fukuma K., Miyamura S., Thoya T., et al. Uterine papillary serous carcinoma with high levels of serum carcinoembryonic antigen. Response to combination chemotherapy. Cancer 1987, 59:403-405.
16. Sachmechi I., Kalra J., Molho L., et al. Paraneoplastic hypercalcemia associated with uterine papillary serous carcinoma. Gynecol Oncol 1995, 58:378-382.
17. Wang J., Wieslander C., Hansen G., et al. Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers. Gynecol Oncol 2006, 101:120-125.
18. Kobel M., Kalloger S.E., Carrick J., et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol 2009, 33:14-21.
19. Sherman M.E., Bitterman P., Rosenshein N.B., et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992, 16:600-610.
20. Carcangiu M.L., Tan L.K., Chambers J.T. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997, 21:1507-1514.
21. Dotto J., Tavassoli F.A. Serous intraepithelial carcinoma arising in an endometrial polyp: a proposal for modification of terminology. Int J Surg Pathol 2008, 16:8-10.
22. Euscher E.D., Malpica A., Deavers M.T., et al. Differential expression of WT-1 in serous carcinomas in the peritoneum with or without associated serous carcinoma in endometrial polyps. Am J Surg Pathol 2005, 29:1074-1078.
23. McCluggage W.G., Sumathi V.P., McManus D.T. Uterine serous carcinoma and endometrial intraepithelial carcinoma arising in endometrial polyps: Report of 5 cases, including 2 associated with tamoxifen therapy. Hum Pathol 2003, 34:939-943.
24. Prat J., Oliva E., Lerma E., et al. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994, 74:1778-1783.
25. Silva E.G., Jenkins R. Serous carcinoma in endometrial polyps. Mod Pathol 1990, 3:120-128.
26. Trahan S., Tetu B., Raymond P.E. Serous papillary carcinoma of the endometrium arising from endometrial polyps: a clinical, histological, and immunohistochemical study of 13 cases. Hum Pathol 2005, 36:1316-1321.
27. Ambros R.A., Sherman M.E., Zahn C.M., et al. Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995, 26:1260-1267.
28. Goff B.A., Kato D., Schmidt R.A., et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994, 54:264-268.
29. Hendrickson M., Ross J., Eifel P., et al. Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982, 6:93-108.
30. Lee K.R., Belinson J.L. Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma. Am J Surg Pathol 1991, 15:965-973.
31. Carcangiu M.L., Chambers J.T. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 1992, 47:298-305.
32. Jordan L.B., Abdul-Kader M., Al-Nafussi A. Uterine serous papillary carcinoma: Histopathologic changes within the female genital tract. Int J Gynecol Cancer 2001, 11:283-289.
33. Posligua L., Malpica A., Liu J., et al. Combined large cell neuroendocrine carcinoma and papillary serous carcinoma of the endometrium with pagetoid spread. Arch Pathol Lab Med 2008, 132:1821-1824.
34. Williams K.E., Waters E.D., Woolas R.P., et al. Mixed serous-endometrioid carcinoma of the uterus: Pathologic and cytopathologic analysis of a high-risk endometrial carcinoma. Int J Gynecol Cancer 1994, 4:7-18.
35. Horn L.C., Hanel C., Bartholdt E., et al. Mixed serous carcinoma of the endometrium with trophoblastic differentiation: analysis of the p53 tumor suppressor gene suggests stem cell origin. Ann Diagn Pathol 2008, 12:1-3.
36. Silverberg S.G., Kurman R.J., Nogales F.F., et al. Tav: Epithelial tumours and related lesions. WHO Classification of Tumours: Pathology and Genetics: Tumours of the Breast and Female Genital Organs 2003, 221-232. IARC Publishing Group, Lyon. F. Tavassoli, P. Devilee (Eds.).
37. Wheeler D.T., Bell K.A., Kurman R.J., et al. Minimal uterine serous carcinoma: Diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000, 24:797-806.
38. Soslow R.A., Slomovitz B.M., Saqi A., et al. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Mullerian serous carcinomas: clinical divergence without immunophenotypic differences. Gynecol Oncol 2000, 79:430-437.
39. Spiegel G.W. Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 1995, 19:417-432.
40. Soslow R.A., Pirog E., Isacson C. Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 2000, 24:726-732.
41. Yan Z., Hui P. Minimal uterine serous carcinoma with extrauterine tumor of identical morphology: An immunohistochemical study of 13 cases. Appl Immunohistochem Mol Morphol 2010, 18:75-79.
42. Rabban J.T., Zaloudek C.J. Minimal uterine serous carcinoma: Current concepts in diagnosis and prognosis. Pathology 2007, 39:125-133.
43. Jarboe E.A., Pizer E.S., Miron A., et al. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol 2009, 22:345-350.
44. Yi X., Zheng W. Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. Curr Opin Obstet Gynecol 2008, 20:20-25.
45. Liang S.X., Chambers S.K., Cheng L., et al. Endometrial glandular dysplasia: A putative precursor lesion of uterine papillary serous carcinoma. Part II: Molecular features. Int J Surg Pathol 2004, 12:319-331.
46. Zheng W., Liang S.X., Yu H., et al. Endometrial glandular dysplasia: A newly defined precursor lesion of uterine papillary serous carcinoma. Part I: Morphologic features. Int J Surg Pathol 2004, 12:207-223.
47. Alkushi A., Clarke B.A., Akbari M., et al. Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 2007, 20:1156-1165.
48. Dupont J., Wang X., Marshall D.S., et al. Wilms tumor gene (WT1) and p53 expression in endometrial carcinomas: A study of 130 cases using a tissue microarray. Gynecol Oncol 2004, 94:449-455.
49. Hirschowitz L., Ganesan R., McCluggage W.G. WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histopathology 2009, 55:478-482.
50. Lomo L., Nucci M.R., Lee K.R., et al. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol 2008, 21:937-942.
51. Tashiro H., Isacson C., Levine R., et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997, 150:177-185.
52. Yemelyanova A., Ji H., Shih IeM., et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: Immunohistochemical analysis of 201 cases. Am J Surg Pathol 2009, 33:1504-1514.
53. O'Neill C.J., McCluggage W.G. p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol 2006, 13:8-15.
54. Reid-Nicholson M., Iyengar P., Hummer A.J., et al. Immunophenotypic diversity of endometrial adenocarcinomas: Implications for differential diagnosis. Mod Pathol 2006, 19:1091-1100.
55. Goldstein N.S., Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002, 117:541-545.
56. Nofech-Mozes S., Khalifa M.A., Ismiil N., et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol 2008, 21:1147-1155.
57. Holcomb K., Delatorre R., Pedemonte B., et al. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. Obstet Gynecol 2002, 100:1290-1295.
58. Schmitz M.J., Hendricks D.T., Farley J., et al. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol Oncol Jun 2000, 77:439-445.
59. Mhawech-Fauceglia P., Herrmann F.R., Rai H., et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol 2010, 133:899-908.
60. Zheng W., Yi X., Fadare O., et al. The oncofetal protein IMP3: A novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008, 32:304-315.
61. Lax S.F. Molecular genetic pathways in various types of endometrial carcinoma: From a phenotypical to a molecular-based classification. Virchows Arch 2004, 444:213-223.
62. Hayes M.P., Ellenson L.H. Molecular alterations in uterine serous carcinoma. Gynecol Oncol 2010, 116:286-289.
63. Zheng W., Cao P., Zheng M., et al. p53 overexpression and Bcl-2 persistence in endometrial carcinoma: Comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996, 61:167-174.
64. Tashiro H., Blazes M.S., Wu R., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997, 57:3935-3940.
65. Odicino F.E., Bignotti E., Rossi E., et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer 2008, 18:14-21.
66. Santin A.D., Bellone S., Gokden M., et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002, 8:1271-1279.
67. Santin A.D., Bellone S., Van Stedum S., et al. Amplification of c-erbB2 oncogene: A major prognostic indicator in uterine serous papillary carcinoma. Cancer 2005, 104:1391-1397.
68. Slomovitz B.M., Broaddus R.R., Burke T.W., et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004, 22:3126-3132.
69. Fleming G.F., Sill M.W., Darcy K.M., et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2010, 116:15-20.
70. Hayes M.P., Douglas W., Ellenson L.H. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol Jun 2009, 113:370-373.
71. Konecny G.E., Santos L., Winterhoff B., et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 2009, 100:89-95.
72. Dainty L.A., Risinger J.I., Morrison C., et al. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. Gynecol Oncol Jun 2007, 105:563-570.
73. Gadducci A., Tana R., Cosio S., et al. Molecular target therapies in endometrial cancer: From the basic research to the clinic. Gynecol Endocrinol 2008, 24:239-249.
74. Konecny G.E., Agarwal R., Keeney G.A., et al. Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol 2008, 109:263-269.
75. Szabo I., Kiss A., Schaff Z. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol Histopathol 2009, 24:1607-1615.
76. Santin A.D., Bellone S., Marizzoni M., et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: Novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer 2007, 109:1312-1322.
77. El-Sahwi K., Bellone S., Cocco E., et al. Overexpression of EpCAM in uterine serous papillary carcinoma: Implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab MT201. Mol Cancer Ther 2010, 9:57-66.
78. Kraus F.T. Irradiation changes in the uterus. The Uterus 1973, 457-488. Williams and Wilkins, Baltimore. H.J. Norris, A.G. Hertig (Eds.).
79. Silverberg S.G., DeGiorgi L.S. Histopathologic analysis of preoperative radiation therapy in endometrial carcinoma. Am J Obstet Gynecol 1974, 119:698-704.
80. Lehman M.B., Hart W.R. Simple and complex hyperplastic papillary proliferations of the endometrium: A clinicopathologic study of nine cases of apparently localized papillary lesions with fibrovascular stromal cores and epithelial metaplasia. Am J Surg Pathol 2001, 25:1347-1354.
81. Hendrickson M.R., Kempson R.L. Endometrial epithelial metaplasias: Proliferations frequently misdiagnosed as adenocarcinoma. Report of 89 cases and proposed classification. Am J Surg Pathol 1980, 4:525-542.
82. Shah S.S., Mazur M.T. Endometrial eosinophilic syncytial change related to breakdown: Immunohistochemical evidence suggests a regressive process. Int J Gynecol Pathol 2008, 27:534-538.
83. Johnson T.L., Kini S.R. Endometrial metaplasia as a source of atypical glandular cells in cervicovaginal smears. Diagn Cytopathol 1996, 14:25-31.
84. Horree N., Heintz A.P., Sie-Go D.M., et al. p16 is consistently expressed in endometrial tubal metaplasia. Cell Oncol 2007, 29:37-45.
85. Ambros R.A., Ballouk F., Malfetano J.H., et al. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am J Surg Pathol 1994, 18:569-575.
86. Ambros R.A., Malfetano J.H. Villoglandular adenocarcinoma of the endometrium. Am J Surg Pathol 2000, 24:155-156.
87. Darvishian F., Hummer A.J., Thaler H.T., et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: A clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 2004, 28:1568-1578.
88. Alvarez T., Bhan A.K., Miller E., et al. Molecular profile of grade 3 endometrial endometrioid carcinoma: Is it a type I or type II endometrial carcinoma?. Mod Pathol 2005, 18(suppl 1):177A.
89. Feng Y.Z., Shiozawa T., Horiuchi A., et al. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas. Virchows Arch 2005, 447:816-822.
90. Halperin R., Zehavi S., Habler L., et al. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001, 22:122-126.
91. Soslow R.A., Shen P.U., Chung M.H., et al. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 1998, 17:129-134.
92. Alkushi A., Kobel M., Kalloger S.E., et al. High-grade endometrial carcinoma: Serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010, 29:343-350.
93. Lax S.F., Pizer E.S., Ronnett B.M., et al. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol Jun 1998, 29:551-558.
94. Acs G., Pasha T., Zhang P.J. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 2004, 23:110-118.
95. Egan J.A., Ionescu M.C., Eapen E., et al. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 2004, 23:119-122.
96. Coosemans A., Moerman P., Verbist G., et al. Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol 2008, 111:502-508.
97. Heatley M.K. WT-1 in ovarian and endometrioid serous carcinoma: A meta-analysis. Histopathology 2005, 46:468.
98. Chiesa-Vottero A.G., Malpica A., Deavers M.T., et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 2007, 26:328-333.
99. Phillips V., Kelly P., McCluggage W.G. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol 2009, 28:179-186.
100. Tong GX, Devaraj K, Hamele-Bena D, et al. PAX8: A marker for carcinoma of Mullerian origin in serous effusions. Diagn Cytopathol, Epub ahead of print July 6, 2010.
101. Alkushi A., Irving J., Hsu F., et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003, 442:271-277.
102. Kamoi S., AlJuboury M.I., Akin M.R. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: Another viewpoint. Int J Gynecol Pathol 2002, 21:217-223.
103. McCluggage W.G., Sumathi V.P., Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology 2001, 39:273-278.
104. McCluggage W.G. Immunohistochemistry as a diagnostic aid in cervical pathology. Pathology 2007, 39:97-111.
105. McCluggage W.G., Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003, 22:231-235.
106. Zhou C., Gilks C.B., Hayes M., et al. Papillary serous carcinoma of the uterine cervix: A clinicopathologic study of 17 cases. Am J Surg Pathol 1998, 22:113-120.
107. Gilks C.B., Clement P.B. Papillary serous adenocarcinoma of the uterine cervix: A report of three cases. Mod Pathol 1992, 5:426-431.
108. McCluggage W.G., Hurrell D.P., Kennedy K. Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: Report of a series of cases. Am J Surg Pathol 2010, 34:735-741.
109. Lee A.H., Paish E.C., Marchio C., et al. The expression of Wilms' tumour-1 and CA125 in invasive micropapillary carcinoma of the breast. Histopathology 2007, 51:824-828.
110. Moritani S., Ichihara S., Hasegawa M., et al. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis?. Hum Pathol 2008, 39:666-671.
111. Tornos C., Soslow R., Chen S., et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005, 29:1482-1489.
112. Nonaka D., Chiriboga L., Soslow R.A. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008, 32:1566-1571.
113. Chambers J.T., Merino M., Kohorn E.I., et al. Uterine papillary serous carcinoma. Obstet Gynecol 1987, 69:109-113.
114. Cirisano F.D., Robboy S.J., Dodge R.K., et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999, 74:385-394.
115. Fader A.N., Boruta D., Olawaiye A.B., et al. Uterine papillary serous carcinoma: Epidemiology, pathogenesis and management. Curr Opin Obstet Gynecol 2010, 22:21-29.
116. Gitsch G., Kohlberger P., Steiner A., et al. Expression of cytokeratins in granulosa cell tumors and ovarian carcinomas. Arch Gynecol Obstet 1992, 251:193-197.
117. Rosenberg P., Boeryd B., Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol 1993, 48:32-37.
118. Carcangiu M.L., Chambers J.T. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: Comparison of clinicopathologic features and survival. Int J Gynecol Pathol 1995, 14:30-38.
119. Soslow R.A., Bissonnette J.P., Wilton A., et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: Similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007, 31:979-987.
120. Abeler V.M., Kjorstad K.E. Serous papillary carcinoma of the endometrium: A histopathological study of 22 cases. Gynecol Oncol 1990, 39:266-271.
121. Bancher-Todesca D., Neunteufel W., Williams K.E., et al. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 1998, 71:344-347.
122. Fader A.N., Drake R.D., O'Malley D.M., et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 2009, 115:2119-2127.
123. Gallion H.H., van Nagell J.R., Powell D.F., et al. Stage I serous papillary carcinoma of the endometrium. Cancer 1989, 63:2224-2228.
124. Hui P., Kelly M., O'Malley D.M., et al. Minimal uterine serous carcinoma: A clinicopathological study of 40 cases. Mod Pathol 2005, 18:75-82.
125. Lim P., Al Kushi A., Gilks B., et al. Early stage uterine papillary serous carcinoma of the endometrium: Effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer 2001, 91:752-757.
126. Fader A.N., Starks D., Gehrig P.A., et al. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2009, 115:244-248.
127. Cocco E., Bellone S., El-Sahwi K., et al. Serum amyloid A (SAA): A novel biomarker for uterine serous papillary cancer. Br J Cancer 2009, 101:335-341.
128. Boruta D.M., Gehrig P.A., Fader A.N., et al. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009, 115:142-153.
129. Hamilton C.A., Kapp D.S., Chan J.K. Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol 2008, 20:26-33.
130. Mendivil A., Schuler K.M., Gehrig P.A. Non-endometrioid adenocarcinoma of the uterine corpus: A review of selected histological subtypes. Cancer Control 2009, 16:46-52.
131. Naumann R.W. Uterine papillary serous carcinoma: state of the state. Curr Oncol Rep 2008, 10:505-511.
132. Rauh-Hain J.A., Growdon W.B., Schorge J.O., et al. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol 2010, 119:299-304.
133. Steed H., Manchul L., Rosen B., et al. Uterine papillary serous carcinoma: Evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy. Int J Gynecol Cancer 2006, 16(suppl 1):278-285.
134. Thomas M.B., Mariani A., Cliby W.A., et al. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol 2007, 107:186-189.
135. Vaidya A.P., Littell R., Krasner C., et al. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer 2006, 16(suppl 1):267-272.
136. Gadducci A., Cosio S., Romanini A., et al. The management of patients with uterine sarcoma: A debated clinical challenge. Crit Rev Oncol/Hematol 2008, 65:129-142.
137. Schwartz P.E. The management of serous papillary uterine cancer. Curr Opin Oncol 2006, 18:494-499.
138. Abeler V.M., Kjorstad K.E. Clear cell carcinoma of the endometrium: A histopathological and clinical study of 97 cases. Gynecol Oncol 1991, 40:207-217.
139. Silverberg S.G., De Giorgi L.S. Clear cell carcinoma of the endometrium. Clinical, pathologic, and ultrastructural findings. Cancer 1973, 31:1127-1140.
140. Christopherson W.M., Alberhasky R.C., Connelly P.J. Carcinoma of the endometrium. I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982, 49:1511-1523.
141. Verloop J., van Leeuwen F.E., Helmerhorst T.J., et al. Cancer risk in DES daughters. Cancer Causes Control 2010, 21:999-1007.
142. Dallenbach-Hellweg G., Hahn U. Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol 1995, 14:7-15.
143. Jensen K.C., Mariappan M.R., Putcha G.V., et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol 2008, 32:1029-1037.
144. Kanbour-Shakir A., Tobon H. Primary clear cell carcinoma of the endometrium: A clinicopathologic study of 20 cases. Int J Gynecol Pathol 1991, 10:67-78.
145. Kurman R.J., Norris H.J. Mesenchymal tumors of the uterus. VI. Epithelioid smooth muscle tumors including leiomyoblastoma and clear-cell leiomyoma: A clinical and pathologic analysis of 26 cases. Cancer 1976, 37:1853-1865.
146. Lee L., Garrett L., Lee H., et al. Association of clear cell carcinoma of the endometrium with a high rate of venous thromboembolism. J Reprod Med 2009, 54:133-138.
147. Hiller N., Sonnenblick M., Hershko C. Paraneoplastic hypercalcemia in endometrial carcinoma. Oncology 1989, 46:45-48.
148. Savvari P., Peitsidis P., Alevizaki M., et al. Paraneoplastic humorally mediated hypercalcemia induced by parathyroid hormone-related protein in gynecologic malignancies: A systematic review. Onkologie 2009, 32:517-523.
149. Malpica A., Tornos C., Burke T.W., et al. Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 1995, 19:769-774.
150. Abeler V.M., Kjorstad K.E., Nesland J.M. Undifferentiated carcinoma of the endometrium. A histopathologic and clinical study of 31 cases. Cancer 1991, 68:98-105.
151. Abeler V.M., Vergote I.B., Kjorstad K.E., et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 1996, 78:1740-1747.
152. Fadare O., Liang S.X., Ulukus E.C., et al. Precursors of endometrial clear cell carcinoma. Am J Surg Pathol 2006, 30:1519-1530.
153. Vang R., Whitaker B.P., Farhood A.I., et al. Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 2001, 20:252-259.
154. Arai T., Watanabe J., Kawaguchi M., et al. Clear cell adenocarcinoma of the endometrium is a biologically distinct entity from endometrioid adenocarcinoma. Int J Gynecol Cancer 2006, 16:391-395.
155. Yalta T., Atay L., Atalay F., et al. E-cadherin expression in endometrial malignancies: Comparison between endometrioid and non-endometrioid carcinomas. J Int Med Res 2009, 37:163-168.
156. Zhang P.J., Williams E., Pasha T., et al. WT1 is expressed in serous, but not in endometrioid, clear cell or mucinous carcinomas of the peritoneum, fallopian tube, ovaries and endometrium. Mod Pathol 2003, 16:216A.
157. Khalifa M.A., Mannel R.S., Haraway S.D., et al. Expression of EGFR, HER-2/neu P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994, 53:84-92.
158. Rolitsky C.D., Theil K.S., McGaughy V.R., et al. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 1999, 18:138-143.
159. Yamamoto S., Tsuda H., Aida S., et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 2007, 38:1074-1080.
160. An H.J., Logani S., Isacson C., et al. Molecular characterization of uterine clear cell carcinoma. Mod Pathol 2004, 17:530-537.
161. Garg K., Shih K., Barakat R., et al. Endometrial carcinomas in women aged 40 years and younger: Tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol 2009, 33:1869-1877.
162. Maxwell G.L., Chandramouli G.V., Dainty L., et al. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. Clin Cancer Res 2005, 11:4056-4066.
163. Risinger J.I., Maxwell G.L., Chandramouli G.V., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 2003, 63:6-11.
164. Zorn K.K., Bonome T., Gangi L., et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005, 11:6422-6430.
165. Moreno-Bueno G., Sanchez-Estevez C., Cassia R., et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003, 63:5697-5702.
166. Arias-Stella J. The Arias-Stella reaction: Facts and fancies four decades after. Adv Anat Pathol 2002, 9:12-23.
167. Tobon H., Watkins G.J. Secretory adenocarcinoma of the endometrium. Int J Gynecol Pathol 1985, 4:328-335.
168. Silva E.G., Young R.H. Endometrioid neoplasms with clear cells: A report of 21 cases in which the alteration is not of typical secretory type. Am J Surg Pathol 2007, 31:1203-1208.
169. Atkins K., Bell S.W., Kempson R.L., et al. Epithelioid smooth muscle tumors of the uterus. Mod Pathol 2001, 14:132A.
170. Iwata J., Fletcher C.D. Immunohistochemical detection of cytokeratin and epithelial membrane antigen in leiomyosarcoma: A systematic study of 100 cases. Pathol Int 2000, 50:7-14.
171. Oliva E., Nielsen G.P., Clement P.B., et al. Epithelioid smooth muscle tumors of the uterus: A clinicopathologic analysis of 80 cases. Mod Pathol 1997, 10:107A.
172. Prayson R.A., Goldblum J.R., Hart W.R. Epithelioid smooth-muscle tumors of the uterus: A clinicopathologic study of 18 patients. Am J Surg Pathol 1997, 21:383-391.
173. Silva E.G., Tornos C., Ordonez N.G., et al. Uterine leiomyosarcoma with clear cell areas. Int J Gynecol Pathol 1995, 14:174-178.
174. Atkins K.A., Arronte N., Darus C.J., et al. The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol 2008, 32:98-102.
175. Oliva E., Young R.H., Amin M.B., et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: A study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol 2002, 26:403-412.
176. Folpe A.L., Mentzel T., Lehr H.A., et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: A clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol 2005, 29:1558-1575.
177. Vang R., Kempson R.L. Perivascular epithelioid cell tumor ("PEComa") of the uterus: A subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors. Am J Surg Pathol 2002, 26:1-13.
178. Lifschitz-Mercer B., Czernobilsky B., Dgani R., et al. Immunocytochemical study of an endometrial diffuse clear cell stromal sarcoma and other endometrial stromal sarcomas. Cancer 1987, 59:1494-1499.
179. Baergen R.N., Rutgers J.L., Young R.H., et al. Placental site trophoblastic tumor: A study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006, 100:511-520.
180. Pelkey T.J., Frierson H.F., Mills S.E., et al. Detection of the alpha-subunit of inhibin in trophoblastic neoplasia. Hum Pathol 1999, 30:26-31.
181. Shih I.M., Kurman R.J. Immunohistochemical localization of inhibin-alpha in the placenta and gestational trophoblastic lesions. Int J Gynecol Pathol 1999, 18:144-150.
182. Shih I.M., Seidman J.D., Kurman R.J. Placental site nodule and characterization of distinctive types of intermediate trophoblast. Hum Pathol Jun 1999, 30:687-694.
183. Nielsen G.P., Oliva E., Young R.H., et al. Alveolar soft-part sarcoma of the female genital tract: A report of nine cases and review of the literature. Int J Gynecol Pathol 1995, 14:283-292.
184. Roma A.A., Yang B., Senior M.E., et al. TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. Int J Gynecol Pathol 2005, 24:131-135.
185. Ladanyi M., Lui M.Y., Antonescu C.R., et al. The der 17t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001, 20:48-57.
186. Creasman W.T., Odicino F., Maisonneuve P., et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet 2006, 95(suppl 1):S105-S143.
187. Hamilton C.A., Cheung M.K., Osann K., et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006, 94:642-646.
188. Fakiris A.J., Henderson M., Lo S.S., et al. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: The Indiana University experience. Brachytherapy 2010, 9:61-65.
189. Gadducci A., Cosio S., Spirito N., et al. Clear cell carcinoma of the endometrium: A biological and clinical enigma. Anticancer Res 2010, 30:1327-1334.
190. Ahluwalia M., Light A.M., Surampudi K., et al. Transitional cell carcinoma of the endometrium: A case report and review of the literature. Int J Gynecol Pathol 2006, 25:378-382.
191. Lininger R.A., Ashfaq R., Albores-Saavedra J., et al. Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation. Cancer 1997, 79:1933-1943.
192. Marino-Enriquez A., Gonzalez-Rocha T., Burgos E., et al. Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation: A clinicopathologic study of 5 cases and review of the literature. Hum Pathol 2008, 39:1606-1613.
193. Spiegel G.W., Austin R.M., Gelven P.L. Transitional cell carcinoma of the endometrium. Gynecol Oncol 1996, 60:325-330.
194. Duic Z., Kukura V., Zovko G., et al. Primary squamous cell carcinoma of endometrium: A case report. Eur J Gynaecol Oncol 2005, 26:106-108.
195. Giordano G., D'Adda T., Merisio C., et al. Primary squamous cell carcinoma of the endometrium: A case report with immunohistochemical and molecular study. Gynecol Oncol 2005, 96:876-879.
196. Goodman A., Zukerberg L.R., Rice L.W., et al. Squamous cell carcinoma of the endometrium: A report of eight cases and a review of the literature. Gynecol Oncol 1996, 61:54-60.
197. Hussain S.F. Verrucous carcinoma of the endometrium. A case report. APMIS 1988, 96:1075-1078.
198. Ryder D.E. Verrucous carcinoma of the endometrium-A unique neoplasm with long survival. Obstet Gynecol 1982, 59(6 suppl):78S-80S.
199. Tchabo N.E., Mhawech-Fauceglia P., Lele S. Primary squamous cell carcinoma of the endometrium: A case report. Eur J Gynaecol Oncol 2008, 29:527-530.
200. Thomakos N., Galaal K., Godfrey K.A., et al. Primary endometrial squamous cell carcinoma. Arch Gynecol Obstet 2008, 278:177-180.
201. Murhekar K., Majhi U., Sridevi V., et al. Does "ichthyosis uteri" have malignant potential?. A case report of squamous cell carcinoma of endometrium associated with extensive ichthyosis uteri. Diagn Pathol 2008, 3:4.
202. Seltzer V.L., Klein M., Beckman E.M. The occurrence of squamous metaplasia as a precursor of squamous cell carcinoma of the endometrium. Obstet Gynecol 1977, 49(1 suppl):34-37.
203. Kataoka A., Nishida T., Sugiyama T., et al. Squamous cell carcinoma of the endometrium with human papillomavirus type 31 and without tumor suppressor gene p53 mutation. Gynecol Oncol 1997, 65:180-184.
204. Horn L.C., Faber S., Bilek K., et al. Expression of COX-2 and HER-2/neu and estrogen and progesterone receptor in primary squamous cell carcinomas of the endometrium. J Cancer Res Clin Oncol 2005, 131:226-228.
205. Zidi Y.S., Bouraoui S., Atallah K., et al. Primary in situ squamous cell carcinoma of the endometrium, with extensive squamous metaplasia and dysplasia. Gynecol Oncol 2003, 88:444-446.
206. Im D.D., Shah K.V., Rosenshein N.B. Report of three new cases of squamous carcinoma of the endometrium with emphasis in the HPV status. Gynecol Oncol 1995, 56:464-469.
207. Chew I., Post M.D., Silvestro C.G. p16 expression in squamous and trophoblastic lesions of the upper female genital tract. Int J Gynecol Pathol 2010, 29:513-522.
208. Baggish M.S., Woodruff J.D. The occurrence of squamous epithelium in the endometrium. Obstet Gynecol Surv 1967, 22:69-115.
209. Tan G.C., Isa M.R., Ng S.P., et al. Unusual form of superficial spreading microinvasive squamous cell carcinoma of uterine cervix involving the endometrium of uterus. J Obstet Gynaecol Res 2004, 30:363-367.
210. Wilson T.O., Podratz K.C., Gaffey T.A., et al. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 1990, 162:418-423. [discussion: 423-416].
211. Erhan Y., Dikmen Y., Yucebilgin M.S., et al. Large cell neuroendocrine carcinoma of the uterine corpus metastatic to brain and lung: Case report and review of the literature. Eur J Gynaecol Oncol 2004, 25:109-112.
212. Eichhorn J.H., Young R.H. Neuroendocrine tumors of the genital tract. Am J Clin Pathol 2001, 115(suppl):S94-S112.
213. Huntsman D.G., Clement P.B., Gilks C.B., et al. Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. Am J Surg Pathol 1994, 18:364-375.
214. van Hoeven K.H., Hudock J.A., Woodruff J.M., et al. Small cell neuroendocrine carcinoma of the endometrium. Int J Gynecol Pathol 1995, 14:21-29.
215. Rajab K.E., Sandhu A.K., Malik A., et al. Small cell neuroendocrine carcinoma of the endometrium, a rare aggressive tumor. Saudi Med J 2005, 26:1130-1132.
216. Mhawech-Fauceglia P., Odunsi K., Dim D., et al. Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: Mystery resolved?. Int J Gynecol Pathol 2008, 27:539-546.
217. Shaco-Levy R., Manor E., Piura B., et al. An unusual composite endometrial tumor combining papillary serous carcinoma and small cell carcinoma. Am J Surg Pathol 2004, 28:1103-1106.
218. Manivel C., Wick M.R., Sibley R.K. Neuroendocrine differentiation in Mullerian neoplasms. An immunohistochemical study of a "pure" endometrial small-cell carcinoma and a mixed mullerian tumor containing small-cell carcinoma. Am J Clin Pathol 1986, 86:438-443.
219. Sato H., Kanai G., Kajiwara H., et al. Small-cell carcinoma of the endometrium presenting as Cushing's syndrome. Endocr J 2010, 57:31-38.
220. Chahud F., Young R.H., Remulla J.F., et al. Bilateral diffuse uveal melanocytic proliferation associated with extraocular cancers: Review of a process particularly associated with gynecologic cancers. Am J Surg Pathol 2001, 25:212-218.
221. Sekiguchi I., Suzuki M., Sato I., et al. Rare case of small-cell carcinoma arising from the endometrium with paraneoplastic retinopathy. Gynecol Oncol 1998, 71:454-457.
222. Albores-Saavedra J., Martinez-Benitez B., Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: Polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol 2008, 27:333-339.
223. Hwang J.H., Lee J.K., Lee N.W., et al. Primary small cell carcinoma of the endometrium: Report of a case with immunochemical studies. J Reprod Med 2010, 55:81-86.
224. Bige O., Saatli B., Secil M., et al. Small cell neuroendocrine carcinoma of the endometrium and laparoscopic staging: A clinicopathologic study of a case and a brief review of the literature. Int J Gynecol Cancer 2008, 18:838-843.
225. Katahira A., Akahira J., Niikura H., et al. Small cell carcinoma of the endometrium: Report of three cases and literature review. Int J Gynecol Cancer 2004, 14:1018-1023.
226. Crowder S., Tuller E. Small cell carcinoma of the female genital tract. Semin Oncol 2007, 34:57-63.
227. Harris N.L., Scully R.E. Malignant lymphoma and granulocytic sarcoma of the uterus and vagina. A clinicopathologic analysis of 27 cases. Cancer 1984, 53:2530-2545.
228. Akbayir O., Gungorduk K., Rafioglu G., et al. Primary primitive neuroectodermal tumor of the uterus: A case report. Arch Gynecol Obstet 2008, 277:345-348.
229. Daya D., Lukka H., Clement P.B. Primitive neuroectodermal tumors of the uterus: A report of four cases. Hum Pathol 1992, 23:1120-1129.